ADR Biomedical Holdings (TSE:3750) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:3750 ADR Biomedical Holdings Inc TSE:3750
27 GF Score
Price 円825.00
GF Value 円38.87
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

TSE:3750
27GF Score
ADR Biomedical Holdings Inc TSE:3750
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円825.00 is trading 2022.5% above its estimated GF Value™ of 円38.87. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Cash Payments:
  • GF Value™: 円38.87 vs. price of 円825.00 (2022.5% above fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
27GF Score

Get the complete analysis for TSE:3750

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円825.00
Price
円38.87
GF Value